Stock MOC MOLECURE S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Molecure S.A.

Equities

MOC

PLONCTH00011

Biotechnology & Medical Research

Market Closed - Warsaw S.E.
Other stock markets
 11:55:42 2024-05-15 EDT 		5-day change 1st Jan Change
14.72 PLN -4.29% Intraday chart for Molecure S.A. +1.66% -24.51%
03-22 Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis CI
01-16 Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I CI

Valuation

Fiscal Period: December 2018 2019 2022 2023 2024 2025
Capitalization 1 195.5 133.7 200.1 247.8 247.8 -
Enterprise Value (EV) 1 143.6 102.2 200.1 187.9 196.1 228
P/E ratio - -32.6 x -13.1 x -15.4 x - -11 x
Yield - - - - - -
Capitalization / Revenue 139 x 65.7 x - 165 x 4.7 x 15.3 x
EV / Revenue 102 x 50.2 x - 125 x 3.72 x 14.1 x
EV / EBITDA -28.4 x -22.3 x - -9.64 x 72.6 x -10.6 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - 1.69 x - 1.64 x 1.64 x 1.97 x
Nbr of stocks (in thousands) 13,670 13,670 14,030 16,836 16,836 -
Reference price 2 14.30 9.780 14.26 15.38 15.38 15.38
Announcement Date 19-04-23 20-03-30 23-03-30 - - -
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2022 2023 2024 2025
Net sales 1 1.409 2.035 - 1.5 52.7 16.2
EBITDA 1 -5.055 -4.587 - -19.5 2.7 -21.6
EBIT 1 -5.12 -4.827 - -21.3 0.8 -23.8
Operating Margin -363.52% -237.21% - -1,420% 1.52% -146.91%
Earnings before Tax (EBT) 1 - -4.166 - -17.4 1.3 -23.5
Net income 1 -4.449 -4.166 -15.26 -17.4 -0.1 -23.8
Net margin -315.83% -204.73% - -1,160% -0.19% -146.91%
EPS 2 - -0.3000 -1.090 -1.000 - -1.400
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-04-23 20-03-30 23-03-30 - - -
1PLN in Million2PLN
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 S1 2022 Q3 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1
Net sales 1 - 0.227 0.981 0.0229 0.2368 0.2 -
EBITDA 1 - -2.856 -3.814 -5.185 -4.684 -6.4 -4
EBIT 1 - -3.087 -4.246 -5.63 -5.141 -6.8 -4.5
Operating Margin - -1,359.89% -432.77% -24,630.14% -2,171.65% -3,400% -
Earnings before Tax (EBT) - - - - - - -
Net income 1 -7.06 -2.296 -3.237 -4.123 -4.145 -6.8 -4.2
Net margin - -1,011.41% -329.94% -18,037.62% -1,750.83% -3,400% -
EPS -0.5000 - - - - - -
Dividend per Share - - - - - - -
Announcement Date 22-09-28 22-10-30 23-04-27 23-09-28 23-10-30 - -
1PLN in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2022 2023 2024 2025
Net Debt 1 - - - - - -
Net Cash position 1 51.9 31.5 - 59.9 51.7 19.8
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) -7.97% -5.17% - - - -
ROA (Net income/ Total Assets) - -4.85% - - - -
Assets 1 - 85.85 - - - -
Book Value Per Share 2 - 5.790 - 9.400 9.400 7.800
Cash Flow per Share - - - - - -
Capex 1 1.51 0.36 - 47 56 33
Capex / Sales 107.06% 17.88% - 3,133.33% 106.26% 203.7%
Announcement Date 19-04-23 20-03-30 23-03-30 - - -
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
15.38 PLN
Average target price
34 PLN
Spread / Average Target
+121.07%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MOLECURE S.A. Stock Molecure S.A.
-24.51% 65.58M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+7.47% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.23% 106B
BIONTECH SE Stock BioNTech SE
-12.50% 22.24B
ARGENX SE Stock argenx SE
+0.44% 21.25B
GENMAB A/S Stock Genmab A/S
-4.18% 18.97B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.85% 18.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.79% 16.81B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.25% 12.54B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.35% 8.09B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MOC Stock
  4. Financials Molecure S.A.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW